



Neumedicines Presents at BARDA and NIAID Sponsored Symposium on Development of Radiation Medical Countermeasures for Licensure

PASADENA, Calif. (January 25, 2013) – Neumedicines Inc., a privately held company developing therapies based on Interleukin-12 (IL-12) as a radiation countermeasure and for the treatment of chemotherapy-induced thrombocytopenia, announces that Timothy K. Gallaher, Chief Analytics Officer, presented today at the Biological Advanced Development and Research Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID) sponsored symposium “Developing Radiation Medical Countermeasures for Licensure: Lessons Learned and Paths Forward.” The two-day symposium was held at the National Institutes of Health (NIH) campus in Bethesda, Maryland.

Dr. Gallaher was one of a number of invited speakers who addressed the meeting of experts in the radiation countermeasure field to discuss lessons learned in the development of countermeasures. The conference was intended for the top companies and researchers in the field to share experiences, so as to further expedite development of this important class of therapeutics for civilian use in the event of a radiation emergency.

Neumedicines is developing HemaMax™ (rHuIL-12) as a post-exposure countermeasure against hematopoietic syndrome of acute radiation syndrome (HSRAS). Studies have established that a single, subcutaneous administration of HemaMax™ without supportive care—no antibiotic, fluids or blood products—can mitigate radiation-induced death when administered 24 hours post-radiation exposure. Additionally, HemaMax™ administered within the effective therapeutic range has been shown to be well-tolerated in humans.

To date, Neumedicines has received a total of \$41 million from BARDA for the development of HemaMax™ as a countermeasure for radiation exposure. Neumedicines expects to receive additional BARDA funds in the second quarter of 2013.

Preclinical and clinical studies have been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contracts No. HHSO1002000800060C and No. HHSO100201100037C

About Neumedicines Inc.

Neumedicines Inc. is developing protein therapeutics that address unmet clinical and societal needs in the fields of oncology, hematology and immunology. The company’s lead product candidate is HemaMax™ (recombinant human interleukin-12, or rHuIL-12), which functions by targeting multiple pathways of hematopoiesis and innate immunity. HemaMax™ is being developed as a biodefense radiation medical countermeasure and for indications in oncology, initially for chemotherapy-induced thrombocytopenia. Neumedicines is committed to developing and maximizing the scientific, clinical and commercial potential of its product pipeline. For more information, please visit www.neumedicines.com or follow the Company on Twitter @Neumedicines.

###